Nuevozen Corp., a San Francisco based Healthcare Artificial Intelligence company developing patient risk assessment and diagnostic solution for cancer and other serious diseases, is pleased to announce the addition of Dr. Rajan Jain, Professor of Radiology and Neurosurgery at NYU Langone Health, to the company’s medical advisory board.
We are deeply honored to have Dr. Jain join our advisory board,” stated Karan Aujla, Nuevozen’ co-founder and CEO. “We look forward to leveraging Dr. Jain’s extensive background and experience in Brain tumor imaging and genomics as we move forward with developing a comprehensive AI platform for cancer screening and diagnosis”.
“I’m truly excited to join Nuevozen’ advisory board and look forward to collaborating with the other key neuro-oncology opinion leaders to help guide the company as they continue to develop their Artificial Intelligence technology,” said Dr. Rajan Jain. “I believe that Artificial Intelligence has the potential to assist Radiologists like me in improving the diagnosis and prognosis of cancer.”
Dr. Jain will provide guidance and advice on Nuevozen’ AI work in the field of Brain tumor imaging. His research interest includes brain tumor imaging, imaging genomics, tumor angiogenesis, perfusion imaging and brain tumor treatment effects. He has published over 150+ papers during the last 20 years in the field of Brain Neoplasms, MRI, Gliomo, Glioblastoma, Tomography and AI. Dr. Jain completed his fellowships from the Vancouver General Hospital and University of Michigan Hospital. He is board certified in Neuroradiology and Diagnostic Radiology.
About Nuevozen Corp.
Founded in 2018, Nuevozen Corp. is a privately held Healthcare AI company located in San Francisco Bay area. Nuevozen’ mission is to help healthcare providers in improving quality and speed of care by utilizing artificial intelligence.
For more information, email info@Nuevozen.com or visit Nuevozen.com.
Media Contact:
Nuevozen Corp.
Karan Aujla
CEO & Co-Founder
karan@nuevozen.com